Accelerating Cancer Therapeutics (ACT)
Accelerating Cancer Therapeutics (ACT) is an accelerator program designed to leverage Columbia’s proficiency in drug discovery and provide access to entrepreneurs and the pharmaceutical industry to advance novel cancer therapeutics from the lab towards the path of commercialization and clinical implementation. The program will provide education, mentorship and funding to help academic translational research projects move beyond the “valley of death” in therapeutic development and reach significant milestones. A key goal of this program is to accelerate translation of novel medical discoveries in cancer from the lab to the clinic by positioning the technology for commercialization. Researchers are also encouraged to submit their funded research outcomes for publication in academic journals, as usual.
- Applications open:
- Friday, Sept. 18, 2020
- Applications due:
- Friday, Nov. 20, 2020
- Cohort announced:
- Wednesdays, 4-6:30PM, Jan - May
- Pitch Day:
2019-2020 Founders' Spotlights
Student Venture Associate Kush Mody interviewed cohort member Dr. Juan Arriaga of Meta Test. Based on research from the lab of Dr. Cory Abate-Shen which specializes in prostate cancer mouse models, Meta Test is a gene signature that will discern which patients are likely to develop metastases.
Student Venture Associate Grace Kim had a chance to virtually sit down with cohort member Dr. Yiping Han of FAP. Dr. Han's lab studies the role of bacterial pathogenesis in cancer.
Cumulative Success Metrics (ACT)
- 3 cycles administered
- 15 applications received
- 15 teams admitted to/went through accelerator
- 11 awards given
- Over $800K in funding awarded by ACT to teams
- $5M in funding awarded to teams by external sources